CLAIMS

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of measuring the amount of MASP-2/C1-INH in a biological sample comprising:

(a) providing a test biological sample from a human subject;

(b) performing an immunoassay comprising capturing and detecting MASP-2/C1-INH complex in the test sample, wherein MASP-2/C1-INH is captured with a monoclonal antibody that specifically binds to human MASP-2; and the MASP-2/C1-INH complex is detected directly or indirectly with an antibody that specifically binds to C1-INH; and

(c) comparing the level of MASP-2/C1-INH complex detected in accordance with (b) with a predetermined level or control sample wherein the level of MASP-2/C1-INH complex detected in the test sample is indicative of the extent of Lectin Pathway Complement activation.

2. The method of claim 1, wherein the biological sample is a fluid sample selected from the group consisting of whole blood, serum, plasma, urine and cerebrospinal fluid.

3. The method of claim 1, wherein the antibody that specifically binds to MASP-2 comprises a binding domain comprising (a) HC-CDR1, HC-CDR2 and HC-CDR3 in a heavy chain variable region set forth as SEQ ID NO:87 and comprising LC-CDR1, LC-CDR2 and LC-CDR3 in a light chain variable region set forth as SEQ ID NO:88, or (b) HC-CDR1, HC-CDR2 and HC-CDR3 in a heavy chain variable region set forth as SEQ ID NO:97 and comprising LC-CDR1, LC-CDR2 and LC-CDR3 in a light chain variable region set forth as SEQ ID NO:98, wherein the CDRs are numbered according to the Kabat numbering system.

4. The method of claim 1, wherein the human subject is currently infected with SARS-CoV-2, or has previously been infected with SARS-CoV-2, or wherein the subject is suffering or at risk for developing another lectin-pathway disease or condition (e.g., HSCT-TMA, IgAN, GvHD or other lectin pathway disease or disorder).

5